Stock News

$0.41 EPS Expected for Fidelity National Financial, Inc. (FNF); Radius Health, Inc. (RDUS) Covered By 8 Bullish Analysts Last Week

Radius Health, Inc. (NASDAQ:RDUS) Logo

Among 12 analysts covering Radius Health (NASDAQ:RDUS), 8 have Buy rating, 0 Sell and 4 Hold. Therefore 67% are positive. Radius Health had 33 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Radius Health, Inc. (NASDAQ:RDUS) has “Buy” rating given on Monday, September 25 by Cantor Fitzgerald. The firm has “Overweight” rating given on Friday, March 23 by Morgan Stanley. Cantor Fitzgerald maintained Radius Health, Inc. (NASDAQ:RDUS) rating on Sunday, June 4. Cantor Fitzgerald has “Buy” rating and $6500 target. Jefferies maintained Radius Health, Inc. (NASDAQ:RDUS) rating on Tuesday, October 10. Jefferies has “Hold” rating and $38.0 target. The rating was maintained by H.C. Wainwright on Wednesday, September 21 with “Buy”. Canaccord Genuity maintained Radius Health, Inc. (NASDAQ:RDUS) on Thursday, September 24 with “Buy” rating. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, July 13. The stock of Radius Health, Inc. (NASDAQ:RDUS) has “Buy” rating given on Monday, May 23 by H.C. Wainwright. Jefferies maintained it with “Hold” rating and $38.0 target in Monday, September 4 report. The company was maintained on Friday, March 24 by H.C. Wainwright. See Radius Health, Inc. (NASDAQ:RDUS) latest ratings:

29/03/2018 Broker: Leerink Swann Rating: Outperform New Target: $53 Initiates Coverage On
23/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $61 New Target: $59 Maintain
02/03/2018 Broker: Jefferies Rating: Hold New Target: $32.0 Maintain
02/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $57 New Target: $61 Maintain
12/02/2018 Broker: JP Morgan Rating: Overweight Old Target: $70 New Target: $60 Maintain
29/01/2018 Broker: Morgan Stanley Rating: Overweight New Target: $57 Initiates Coverage On
08/12/2017 Broker: Cowen & Co Rating: Hold
06/12/2017 Broker: Citigroup Rating: Hold New Target: $30.0 Initiate
02/11/2017 Broker: Jefferies Rating: Hold New Target: $31.0 Maintain

Analysts expect Fidelity National Financial, Inc. (NYSE:FNF) to report $0.41 EPS on May, 2 after the close.They anticipate $0.01 EPS change or 2.38% from last quarter’s $0.42 EPS. FNF’s profit would be $112.54M giving it 23.69 P/E if the $0.41 EPS is correct. After having $0.60 EPS previously, Fidelity National Financial, Inc.’s analysts see -31.67% EPS growth. The stock decreased 0.74% or $0.29 during the last trading session, reaching $38.85. About 45,406 shares traded. Fidelity National Financial, Inc. (NYSE:FNF) has risen 46.00% since April 18, 2017 and is uptrending. It has outperformed by 34.45% the S&P500.

Among 8 analysts covering Fidelity National Financial (NYSE:FNF), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Fidelity National Financial had 26 analyst reports since August 3, 2015 according to SRatingsIntel. The company was maintained on Wednesday, January 31 by Piper Jaffray. The stock of Fidelity National Financial, Inc. (NYSE:FNF) earned “Buy” rating by Monness Crespi & Hardt on Friday, November 4. Keefe Bruyette & Woods maintained the stock with “Hold” rating in Thursday, December 21 report. The rating was downgraded by Wood to “Market Perform” on Monday, July 18. The rating was maintained by Piper Jaffray with “Buy” on Monday, December 18. The rating was maintained by Monness Crespi & Hardt with “Buy” on Monday, January 25. Piper Jaffray maintained the stock with “Overweight” rating in Friday, September 25 report. The stock of Fidelity National Financial, Inc. (NYSE:FNF) has “Hold” rating given on Friday, September 8 by Keefe Bruyette & Woods. The firm earned “Hold” rating on Thursday, July 20 by Keefe Bruyette & Woods. On Thursday, February 1 the stock rating was maintained by Stephens with “Buy”.

Fidelity National Financial, Inc., together with its subsidiaries, provides title insurance, technology, and transaction services to the real estate and mortgage industries in the United States. The company has market cap of $10.66 billion. It offers title insurance, escrow, and other title related services, including collection and trust activities, trustee sales guarantees, recordings and conveyances, and home warranty insurance. It has a 16.32 P/E ratio. The firm also offers information used by title insurance underwriters, title agents, and closing attorneys to underwrite title insurance policies for real property sales and transfer.

Investors sentiment increased to 1.44 in Q4 2017. Its up 0.23, from 1.21 in 2017Q3. It improved, as 40 investors sold Fidelity National Financial, Inc. shares while 87 reduced holdings. 53 funds opened positions while 130 raised stakes. 219.60 million shares or 1.84% more from 215.64 million shares in 2017Q3 were reported. 2,511 were reported by Northwestern Mutual Wealth Mngmt Co. Millennium Ltd Liability Co, a New York-based fund reported 505,304 shares. Shine Investment Advisory Services Inc has 1,005 shares for 0.02% of their portfolio. Tarbox Family Office Inc accumulated 875 shares. Pr Herzig And owns 6,931 shares or 0.52% of their US portfolio. Bokf Na stated it has 0.06% in Fidelity National Financial, Inc. (NYSE:FNF). Atlantic Tru Group Ltd holds 0% of its portfolio in Fidelity National Financial, Inc. (NYSE:FNF) for 14,543 shares. Moreover, Horizon Kinetics Ltd Co has 0.05% invested in Fidelity National Financial, Inc. (NYSE:FNF). Nuveen Asset Mgmt Ltd Liability reported 0.01% of its portfolio in Fidelity National Financial, Inc. (NYSE:FNF). Paradigm Cap Mgmt Inc Ny stated it has 34,293 shares or 0.11% of all its holdings. First Personal Serv reported 638 shares or 0% of all its holdings. Gotham Asset Limited Company has 10,905 shares. Eii Cap Management reported 31,390 shares. Arizona State Retirement System reported 0.09% of its portfolio in Fidelity National Financial, Inc. (NYSE:FNF). Gam Hldg Ag owns 39,767 shares or 0.05% of their US portfolio.

Since October 26, 2017, it had 3 insider buys, and 0 sales for $5.98 million activity. BIOTECH GROWTH N V bought $1.83 million worth of stock.

Investors sentiment decreased to 1.36 in 2017 Q4. Its down 0.01, from 1.37 in 2017Q3. It worsened, as 23 investors sold Radius Health, Inc. shares while 24 reduced holdings. 16 funds opened positions while 48 raised stakes. 53.59 million shares or 2.56% more from 52.25 million shares in 2017Q3 were reported. Morgan Stanley holds 0% or 262,907 shares. Camber Capital Mngmt invested in 1.00 million shares. Sg Americas Securities Limited has 4,178 shares. Contravisory Inv Mgmt Inc invested 0% of its portfolio in Radius Health, Inc. (NASDAQ:RDUS). Royal Bancorp Of Canada holds 0% of its portfolio in Radius Health, Inc. (NASDAQ:RDUS) for 4,106 shares. Sector Gamma As accumulated 52,173 shares. Rhumbline Advisers has 36,058 shares for 0% of their portfolio. Profund Ltd Liability reported 0.02% stake. 1.87 million are held by Timessquare Cap Mgmt Lc. Walleye Trading Limited Liability Co has 0% invested in Radius Health, Inc. (NASDAQ:RDUS) for 5,019 shares. 14,525 are held by Weiss Asset Mngmt Lp. Fmr Limited Liability Com invested in 0.01% or 3.04 million shares. Td Asset owns 127,170 shares for 0.01% of their portfolio. Evercore Wealth Management Lc, New York-based fund reported 6,435 shares. Gru One Trading Ltd Partnership has invested 0% in Radius Health, Inc. (NASDAQ:RDUS).

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. The company has market cap of $1.60 billion. The Company’s product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. It currently has negative earnings. The firm is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer.

Fidelity National Financial, Inc. (NYSE:FNF) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *